Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

June 28, 2024

Conditions
Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
Interventions
DRUG

IDX-1197

Until progression or unacceptable toxicity develops

Trial Locations (19)

10408

National Cancer Centre, Goyang

13496

Cha University Bundang Medical Center, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

16499

Ajou University Hospital, Suwon

21565

Gachon University Gil Medical Center, Incheon

48108

Inje University Haeundae Hospital, Busan

49201

Dong-a University Hospital, Busan

50612

Pusan National University Yangsan Hospital, Busan

52727

Gyeongsang National University Hospital, Jinju

58128

Chonnam National University Hwasun Hospital, Hwasun

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03181

Kangbuk Samsung Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

07061

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Idience Co., Ltd.

INDUSTRY

NCT04174716 - Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS) | Biotech Hunter | Biotech Hunter